Ticagrelor Increases Platelet-Mediated Staphylococcus aureus Killing, Resulting in Clearance of Bacteremia.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 33966075.
- Also identified by DOI 10.1093/infdis/jiab146 and PMC identifier 8599881.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Platelets are a critical immune defense against Staphylococcus aureus bloodstream infections. Staphylococcus aureus α-toxin is a virulence factor that decreases platelet viability and accelerates platelet clearance. It has been shown that ticagrelor blocks α-toxin-mediated platelet injury and resulting thrombocytopenia, protecting mice in a lethal S. aureus sepsis model. We now present the use of ticagrelor as adjunctive therapy in a patient with a S. aureus endovascular infection and thrombocytopenia, associated with restoration of platelet count and bacteremia clearance. Ticagrelor enhanced platelet killing of the S. aureus bloodstream isolate from the treated patient in vitro.
Medical subject headings
- Blood Platelets
- Platelet Aggregation Inhibitors
- Purinergic P2Y Receptor Antagonists
- Staphylococcal Infections
- Staphylococcus aureus
- Ticagrelor